噻托溴铵奥达特罗能倍乐的副作用有哪些

It contains two active substances, tiotropium bromide and olodaterol, both of which are long-acting bronchodilators. Respimat helps adults with chronic obstructive pulmonary disease (COPD) breathe easier. COPD is a long-term lung disease that causes shortness of breath and coughing. Respimat helps open the airways, making it easier for air to move in and out of the lungs. Normal use of Respimat can also relieve persistent shortness of breath caused by the disease, helping to minimize the impact of the disease on daily life.

Tiotropium bromide, olodaterol and Respimat is a long-acting anticholinergic drug that has a selective inhibitory effect on M3 receptors. It has the advantages of long maintenance of blood concentration and few side effects. Let’s take a look at some of the side effects of tiotropium bromide, olodaterol and Respimat during treatment.

A common side effect of tiotropium, olodaterol, and Respimat is dry mouth. Less common side effects include dizziness, headache, difficulty sleeping (insomnia), high blood pressure, irregular heartbeat (atrial fibrillation), fast heartbeat (tachycardia), feeling the heart beat (palpitations), cough, and constipation.

The use of this medicine is contraindicated if the patient is allergic to tiotropium bromide, olodaterol, Respimat or its components. Some patients may experience immediate allergic reactions after using Respimat, such as rash, hives, swelling of the mouth and face, sudden difficulty breathing (angioedema), or other allergic reactions (such as a sudden drop in blood pressure or dizziness) that may occur alone or as part of a severe allergic reaction. If any of the above conditions occur, stop using this medicine and consult your doctor immediately.

The above are the possible side effects of tiotropium bromide and olodaterol. Since each patient's physical condition is not exactly the same, patients are advised to follow the doctor's instructions during treatment and use the medication correctly.

Recommended related hot articles: /newsDetail/83799.html